Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation

Cell Stem Cell

Volumn 4, Issue 4, 2009, Pages 289-300

  Kiuru, Maija ^a   Boyer, Julie L ^a   O'Connor, Timothy P ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GANCICLOVIR; THYMIDINE KINASE;

APOPTOSIS; CANCER GENE THERAPY; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SELECTION; CELL TYPE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DAUGHTER CELL; DISEASE CONTROL; DNA MODIFICATION; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE TRANSFER; GENETIC REGULATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; SUICIDE GENE; TARGET CELL; TERATOCARCINOMA; TERATOMA;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENES, TRANSGENIC, SUICIDE; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; NEOPLASTIC STEM CELLS; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 62949195751     PISSN: 19345909     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.stem.2009.03.010     Document Type: Review

References (156)

1. Addis R.C., Bulte J.W., and Gearhart J.D. Special cells, special considerations: the challenges of bringing embryonic stem cells from the laboratory to the clinic. Clin. Pharmacol. Ther. 83 (2008) 386-389
2. Amariglio N., Hirshberg A., Scheithauer B.W., Cohen Y., Loewenthal R., Trakhtenbrot L., Paz N., Koren-Michowitz M., Waldman D., Leider-Trejo L., et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 6 (2009) e1000029 10.1371/journal.pmed.1000029
3. Amit M., and Itskovitz-Eldor J. Derivation and spontaneous differentiation of human embryonic stem cells. J. Anat. 200 (2002) 225-232
4. Aractingi S., Kanitakis J., Euvrard S., Le D.C., Peguillet I., Khosrotehrani K., Lantz O., and Carosella E.D. Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res. 65 (2005) 1755-1760
5. Arafat W.O., Gomez-Navarro J., Xiang J., Barnes M.N., Mahasreshti P., Alvarez R.D., Siegal G.P., Badib A.O., Buchsbaum D., Curiel D.T., and Stackhouse M.A. An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer. Mol. Ther. 1 (2000) 545-554
6. Asahina K., Teramoto K., and Teraoka H. Embryonic stem cells: hepatic differentiation and regenerative medicine for the treatment of liver disease. Curr. Stem Cell Res. Ther. 1 (2006) 139-156
7. Avital I., Moreira A.L., Klimstra D.S., Leversha M., Papadopoulos E.B., Brennan M., and Downey R.J. Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 25 (2007) 2903-2909
8. Barozzi P., Luppi M., Facchetti F., Mecucci C., Alu M., Sarid R., Rasini V., Ravazzini L., Rossi E., Festa S., et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat. Med. 9 (2003) 554-561
9. Ben-Hur T., Idelson M., Khaner H., Pera M., Reinhartz E., Itzik A., and Reubinoff B.E. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 22 (2004) 1246-1255
10. Berger C., Flowers M.E., Warren E.H., and Riddell S.R. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107 (2006) 2294-2302
11. Blum B., and Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv. Cancer Res. 100 (2008) 133-158
12. Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Traversari C., and Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1997) 1719-1724
13. Bonini C., Bondanza A., Perna S.K., Kaneko S., Traversari C., Ciceri F., and Bordignon C. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol. Ther. 15 (2007) 1248-1252
14. Boshart M., Weber F., Jahn G., Dorsch-Hasler K., Fleckenstein B., and Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41 (1985) 521-530
15. Brickman J.M., and Burdon T.G. Pluripotency and tumorigenicity. Nat. Genet. 32 (2002) 557-558
16. Brooks A.R., Harkins R.N., Wang P., Qian H.S., Liu P., and Rubanyi G.M. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J. Gene Med. 6 (2004) 395-404
17. Burcin M.M., O'Malley B.W., and Tsai S.Y. A regulatory system for target gene expression. Front. Biosci. 3 (1998) c1-c7
18. Cao F., Lin S., Xie X., Ray P., Patel M., Zhang X., Drukker M., Dylla S.J., Connolly A.J., Chen X., et al. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 113 (2006) 1005-1014
19. Cao F., Drukker M., Lin S., Sheikh A.Y., Xie X., Li Z., Connolly A.J., Weissman I.L., and Wu J.C. Molecular imaging of embryonic stem cell misbehavior and suicide gene ablation. Cloning Stem Cells 9 (2007) 107-117
20. Carpenter M.K., Rosler E., and Rao M.S. Characterization and differentiation of human embryonic stem cells. Cloning Stem Cells 5 (2003) 79-88
21. Corsten M.F., and Shah K. Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol. 9 (2008) 376-384
22. Couzin J. Celebration and concern over U.S. trial of embryonic stem cells. Science 323 (2009) 568
23. Cowan C.A., Atienza J., Melton D.A., and Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 309 (2005) 1369-1373
24. Cross D., and Burmester J.K. Gene therapy for cancer treatment: past, present and future. Clin. Med. Res. 4 (2006) 218-227
25. Crystal R.G. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother. Pharmacol. 43 Suppl (1999) S90-S99
26. Curtin J.F., Candolfi M., Puntel M., Xiong W., Muhammad A.K., Kroeger K., Mondkar S., Liu C., Bondale N., Lowenstein P.R., and Castro M.G. Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators. Methods Mol. Biol. 434 (2008) 239-266
27. Darabi R., Gehlbach K., Bachoo R.M., Kamath S., Osawa M., Kamm K.E., Kyba M., and Perlingeiro R.C. Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat. Med. 14 (2008) 134-143
28. Denny W.A. Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest. 22 (2004) 604-619
29. Docherty K., Bernardo A.S., and Vallier L. Embryonic stem cell therapy for diabetes mellitus. Semin. Cell Dev. Biol. 18 (2007) 827-838
30. Draper J.S., Smith K., Gokhale P., Moore H.D., Maltby E., Johnson J., Meisner L., Zwaka T.P., Thomson J.A., and Andrews P.W. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat. Biotechnol. 22 (2004) 53-54
31. Dubernard G., Aractingi S., Oster M., Rouzier R., Mathieu M.C., Uzan S., and Khosrotehrani K. Breast cancer stroma frequently recruits fetal derived cells during pregnancy. Breast Cancer Res. 10 (2008) R14
32. Durcova-Hills G., Tang F., Doody G., Tooze R., and Surani M.A. Reprogramming primordial germ cells into pluripotent stem cells. PLoS ONE 3 (2008) e3531 10.1371/journal.pone.0003531
33. Evans M.J., and Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 292 (1981) 154-156
34. Fairchild P.J., Cartland S., Nolan K.F., and Waldmann H. Embryonic stem cells and the challenge of transplantation tolerance. Trends Immunol. 25 (2004) 465-470
35. Fan L., Freeman K.W., Khan T., Pham E., and Spencer D.M. Improved artificial death switches based on caspases and FADD. Hum. Gene Ther. 10 (1999) 2273-2285
36. Fehse B., Richters A., Putimtseva-Scharf K., Klump H., Li Z., Ostertag W., Zander A.R., and Baum C. CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol. Ther. 1 (2000) 448-456
37. Fischbach G.D., and Fischbach R.L. Stem cells: science, policy, and ethics. J. Clin. Invest. 114 (2004) 1364-1370
38. Foecking M.K., and Hofstetter H. Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene 45 (1986) 101-105
39. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (2001) 710-719
40. Fujikawa T., Oh S.H., Pi L., Hatch H.M., Shupe T., and Petersen B.E. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am. J. Pathol. 166 (2005) 1781-1791
41. Gadi V.K., Alexander S.D., Waud W.R., Allan P.W., Parker W.B., and Sorscher E.J. A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J. Pharmacol. Exp. Ther. 304 (2003) 1280-1284
42. Gage F.H. Mammalian neural stem cells. Science 287 (2000) 1433-1438
43. Gerrard L., Zhao D., Clark A.J., and Cui W. Stably transfected human embryonic stem cell clones express OCT4-specific green fluorescent protein and maintain self-renewal and pluripotency. Stem Cells 23 (2005) 124-133
44. Giudice A., and Trounson A. Genetic modification of human embryonic stem cells for derivation of target cells. Cell Stem Cell 2 (2008) 422-433
45. Golfinopoulos V., Pentheroudakis G., Kamakari S., Metaxa-Mariatou V., and Pavlidis N. Donor-derived breast cancer in a bone marrow transplantation recipient. Breast Cancer Res. Treat. 113 (2009) 211-213
46. Gordon M.Y. Stem cells for regenerative medicine-biological attributes and clinical application. Exp. Hematol. 36 (2008) 726-732
47. Gossen M., and Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89 (1992) 5547-5551
48. Goverdhana S., Puntel M., Xiong W., Zirger J.M., Barcia C., Curtin J.F., Soffer E.B., Mondkar S., King G.D., Hu J., et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 12 (2005) 189-211
49. Greaves M.F. Cord blood donor cell leukemia in recipients. Leukemia 20 (2006) 1633-1634
50. Hacein-Bey-Abina S., Von K.C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
51. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118 (2008) 3132-3142
52. Hara A., Aoki H., Taguchi A., Niwa M., Yamada Y., Kunisada T., and Mori H. Neuron-like differentiation and selective ablation of undifferentiated embryonic stem cells containing suicide gene with Oct-4 promoter. Stem Cells Dev. 17 (2008) 619-627
53. Harrison N.J., Baker D., and Andrews P.W. Culture adaptation of embryonic stem cells echoes germ cell malignancy. Int. J. Androl. 30 (2007) 275-281
54. Hedley D., Ogilvie L., and Springer C. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat. Rev. Cancer 7 (2007) 870-879
55. Hedlund E., Hefferan M.P., Marsala M., and Isacson O. Cell therapy and stem cells in animal models of motor neuron disorders. Eur. J. Neurosci. 26 (2007) 1721-1737
56. Hentze H., Graichen R., and Colman A. Cell therapy and the safety of embryonic stem cell-derived grafts. Trends Biotechnol. 25 (2007) 24-32
57. Hewitt Z., Priddle H., Thomson A.J., Wojtacha D., and McWhir J. Ablation of undifferentiated human embryonic stem cells: exploiting innate immunity against the Gal alpha1-3Galbeta1-4GlcNAc-R (alpha-Gal) epitope. Stem Cells 25 (2007) 10-18
58. Hochedlinger K., and Jaenisch R. Monoclonal mice generated by nuclear transfer from mature B and T donor cells. Nature 415 (2002) 1035-1038
59. Hochedlinger K., and Jaenisch R. Nuclear reprogramming and pluripotency. Nature 441 (2006) 1061-1067
60. Hodges H., Pollock K., Stroemer P., Patel S., Stevanato L., Reuter I., and Sinden J. Making stem cell lines suitable for transplantation. Cell Transplant. 16 (2007) 101-115
61. Hu M.C., and Davidson N. The inducible lac operator-repressor system is functional for control of expression of injected DNA in Xenopus oocytes. Gene 62 (1988) 301-313
62. Introna M., Barbui A.M., Bambacioni F., Casati C., Gaipa G., Borleri G., Bernasconi S., Barbui T., Golay J., Biondi A., and Rambaldi A. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum. Gene Ther. 11 (2000) 611-620
63. Jung J., Hackett N.R., Pergolizzi R.G., Pierre-Destine L., Krause A., and Crystal R.G. Ablation of tumor-derived stem cells transplanted to the central nervous system by genetic modification of embryonic stem cells with a suicide gene. Hum. Gene Ther. 18 (2007) 1182-1192
64. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev. 19 (2005) 1129-1155
65. Kim J.B., Sebastiano V., Wu G., Araúzo-Bravo M.J., Sasse P., Gentile L., Ko K., Ruau D., Ehrich M., van den Boom D., et al. Oct4-induced pluripotency in adult neural stem cells. Cell 136 (2009) 411-419
66. Kirn D., Niculescu-Duvaz I., Hallden G., and Springer C.J. The emerging fields of suicide gene therapy and virotherapy. Trends Mol. Med. 8 (2002) S68-S73
67. Kleinsmith L.J., and Pierce Jr. G.B. Multipotentiality of single embryonal carcinoma cells. Cancer Res. 24 (1964) 1544-1551
68. Klimanskaya I., Chung Y., Becker S., Lu S.J., and Lanza R. Human embryonic stem cell lines derived from single blastomeres. Nature 444 (2006) 481-485
69. Kock H., Harris M.P., Anderson S.C., Machemer T., Hancock W., Sutjipto S., Wills K.N., Gregory R.J., Shepard H.M., Westphal M., and Maneval D.C. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int. J. Cancer 67 (1996) 808-815
70. Koehne G., Gallardo H.F., Sadelain M., and O'Reilly R.J. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood 96 (2000) 109-117
71. Korbling M., Katz R.L., Khanna A., Ruifrok A.C., Rondon G., Albitar M., Champlin R.E., and Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N. Engl. J. Med. 346 (2002) 738-746
72. Kubo A., Shinozaki K., Shannon J.M., Kouskoff V., Kennedy M., Woo S., Fehling H.J., and Keller G. Development of definitive endoderm from embryonic stem cells in culture. Development 131 (2004) 1651-1662
73. Laflamme M.A., and Murry C.E. Regenerating the heart. Nat. Biotechnol. 23 (2005) 845-856
74. Lau D., Ogbogu U., Taylor B., Stafinski T., Menon D., and Caulfield T. Stem cell clinics online: The direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 3 (2008) 591-594
75. Lawrenz B., Schiller H., Willbold E., Ruediger M., Muhs A., and Esser S. Highly sensitive biosafety model for stem-cell-derived grafts. Cytotherapy 6 (2004) 212-222
76. Lerou P.H., and Daley G.Q. Therapeutic potential of embryonic stem cells. Blood Rev. 19 (2005) 321-331
77. Li M., Price D., and Smith A. Lineage selection and isolation of neural precursors from embryonic stem cells. Symp. Soc. Exp. Biol. (2001) 29-42
78. Li C., Bowles D.E., van Dyke T., and Samulski R.J. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 12 (2005) 913-925
79. Liu T.J., Zhang W.W., Taylor D.L., Roth J.A., Goepfert H., and Clayman G.L. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 54 (1994) 3662-3667
80. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., Clark A.T., and Plath K. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc. Natl. Acad. Sci. USA 105 (2008) 2883-2888
81. Maherali N., Sridharan R., Xie W., Utikal J., Eminli S., Arnold K., Stadtfeld M., Yachechko R., Tchieu J., Jaenisch R., et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1 (2007) 55-70
82. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. USA 78 (1981) 7634-7638
83. Martin M.J., Muotri A., Gage F., and Varki A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 11 (2005) 228-232
84. Mattsson J., Jansson M., Wernerson A., and Hassan M. Lung epithelial cells and type II pneumocytes of donor origin after allogeneic hematopoietic stem cell transplantation. Transplantation 78 (2004) 154-157
85. Mayhall E.A., Paffett-Lugassy N., and Zon L.I. The clinical potential of stem cells. Curr. Opin. Cell Biol. 16 (2004) 713-720
86. Miccio A., Cesari R., Lotti F., Rossi C., Sanvito F., Ponzoni M., Routledge S.J., Chow C.M., Antoniou M.N., and Ferrari G. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc. Natl. Acad. Sci. USA 105 (2008) 10547-10552
87. Miletic H., Fischer Y.H., Giroglou T., Rueger M.A., Winkeler A., Li H., Himmelreich U., Stenzel W., Jacobs A.H., and von Laer D. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin. Cancer Res. 13 (2007) 6761-6768
88. Minami E., Laflamme M.A., Saffitz J.E., and Murry C.E. Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation 112 (2005) 2951-2958
89. Nair V. Retrovirus-induced oncogenesis and safety of retroviral vectors. Curr. Opin. Mol. Ther. 10 (2008) 431-438
90. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., Okita K., Mochiduki Y., Takizawa N., and Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26 (2008) 101-106
91. Nakayama K., Pergolizzi R.G., and Crystal R.G. Gene transfer-mediated pre-mRNA segmental trans-splicing as a strategy to deliver intracellular toxins for cancer therapy. Cancer Res. 65 (2005) 254-263
92. Naumann U., Schmidt F., Wick W., Frank B., Weit S., Gillissen B., Daniel P., and Weller M. Adenoviral natural born killer gene therapy for malignant glioma. Hum. Gene Ther. 14 (2003) 1235-1246
93. Ngan E.S., Ma Z.Q., Chua S.S., DeMayo F.J., and Tsai S.Y. Inducible expression of FGF-3 in mouse mammary gland. Proc. Natl. Acad. Sci. USA 99 (2002) 11187-11192
94. Niculescu-Duvaz I., and Springer C.J. Introduction to the background, principles, and state of the art in suicide gene therapy. Methods Mol. Med. 90 (2004) 1-27
95. Nishikawa S., Goldstein R.A., and Nierras C.R. The promise of human induced pluripotent stem cells for research and therapy. Nat. Rev. Mol. Cell Biol. 9 (2008) 725-729
96. Noggle S.A., James D., and Brivanlou A.H. A molecular basis for human embryonic stem cell pluripotency. Stem Cell Rev. 1 (2005) 111-118
97. O'Connor T.P., and Crystal R.G. Genetic medicines: treatment strategies for hereditary disorders. Nat. Rev. Genet. 7 (2006) 261-276
98. Oh S.K., and Choo A.B. Human embryonic stem cells: technological challenges towards therapy. Clin. Exp. Pharmacol. Physiol. 33 (2006) 489-495
99. Okamoto R., Yajima T., Yamazaki M., Kanai T., Mukai M., Okamoto S., Ikeda Y., Hibi T., Inazawa J., and Watanabe M. Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat. Med. 8 (2002) 1011-1017
100. Okita K., Ichisaka T., and Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 448 (2007) 313-317
101. Orchard P.J., Blazar B.R., Burger S., Levine B., Basso L., Nelson D.M., Gordon K., McIvor R.S., Wagner J.E., and Miller J.S. Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum. Gene Ther. 13 (2002) 979-988
102. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., Lerou P.H., Lensch M.W., and Daley G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451 (2008) 141-146
103. Park K., Kim W.J., Cho Y.H., Lee Y.I., Lee H., Jeong S., Cho E.S., Chang S.I., Moon S.K., Kang B.S., et al. Cancer gene therapy using adeno-associated virus vectors. Front. Biosci. 13 (2008) 2653-2659
104. Pastan I., Hassan R., Fitzgerald D.J., and Kreitman R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6 (2006) 559-565
105. Portsmouth D., Hlavaty J., and Renner M. Suicide genes for cancer therapy. Mol. Aspects Med. 28 (2007) 4-41
106. Price F.D., Kuroda K., and Rudnicki M.A. Stem cell based therapies to treat muscular dystrophy. Biochim. Biophys. Acta 1772 (2007) 272-283
107. Quaini F., Urbanek K., Beltrami A.P., Finato N., Beltrami C.A., Nadal-Ginard B., Kajstura J., Leri A., and Anversa P. Chimerism of the transplanted heart. N. Engl. J. Med. 346 (2002) 5-15
108. Raki M., Rein D.T., Kanerva A., and Hemminki A. Gene transfer approaches for gynecological diseases. Mol. Ther. 14 (2006) 154-163
109. Rein D.T., Breidenbach M., and Curiel D.T. Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2 (2006) 137-143
110. Riddell S.R., Elliott M., Lewinsohn D.A., Gilbert M.J., Wilson L., Manley S.A., Lupton S.D., Overell R.W., Reynolds T.C., Corey L., and Greenberg P.D. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2 (1996) 216-223
111. Rippon H.J., and Bishop A.E. Embryonic stem cells. Cell Prolif. 37 (2004) 23-34
112. Rivera V.M., Clackson T., Natesan S., Pollock R., Amara J.F., Keenan T., Magari S.R., Phillips T., Courage N.L., Cerasoli Jr. F., et al. A humanized system for pharmacologic control of gene expression. Nat. Med. 2 (1996) 1028-1032
113. Robinet E., Fehse B., Ebeling S., Sauce D., Ferrand C., and Tiberghien P. Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function. Cytotherapy 7 (2005) 150-157
114. Roorda B.D., ter Elst A., Kamps W.A., and de Bont E.S. Bone marrow-derived cells and tumor growth: Contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit. Rev. Oncol. Hematol. 69 (2009) 187-198
115. Roy N.S., Cleren C., Singh S.K., Yang L., Beal M.F., and Goldman S.A. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12 (2006) 1259-1268
116. Sauce D., Bodinier M., Garin M., Petracca B., Tonnelier N., Duperrier A., Melo J.V., Apperley J.F., Ferrand C., Herve P., et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 99 (2002) 1165-1173
117. Schaedel O., and Reiter Y. Antibodies and their fragments as anti-cancer agents. Curr. Pharm. Des. 12 (2006) 363-378
118. Scheidemann F., Therrien J.P., and Pfutzner W. Selectable bicistronic vectors in skin gene therapy. Arch. Dermatol. Res. 300 (2008) 415-423
119. Schuldiner M., Itskovitz-Eldor J., and Benvenisty N. Selective ablation of human embryonic stem cells expressing a "suicide" gene. Stem Cells 21 (2003) 257-265
120. Shinoura N., Yoshida Y., Sadata A., Hanada K.I., Yamamoto S., Kirino T., Asai A., and Hamada H. Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. Hum. Gene Ther. 9 (1998) 1983-1993
121. Shinoura N., Yoshida Y., Asai A., Kirino T., and Hamada H. Relative level of expression of Bax and Bcl-XL determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. Oncogene 18 (1999) 5703-5713
122. Shinoura N., Koike H., Furitu T., Hashimoto M., Asai A., Kirino T., and Hamada H. Adenovirus-mediated transfer of caspase-8 augments cell death in gliomas: implication for gene therapy. Hum. Gene Ther. 11 (2000) 1123-1137
123. Shinoura N., Ohashi M., Yoshida Y., Kirino T., Asai A., Hashimoto M., and Hamada H. Adenovirus-mediated overexpression of Fas induces apoptosis of gliomas. Cancer Gene Ther. 7 (2000) 224-232
124. Shinoura N., Yamamoto N., Asai A., Kirino T., and Hamada H. Adenovirus-mediated transfer of Fas ligand gene augments radiation-induced apoptosis in U-373MG glioma cells. Jpn. J. Cancer Res. 91 (2000) 1044-1050
125. Shinoura N., Sakurai S., Asai A., Kirino T., and Hamada H. Co-transduction of Apaf-1 and caspase-9 augments etoposide-induced apoptosis in U-373MG glioma cells. Jpn. J. Cancer Res. 92 (2001) 467-474
126. Shinoura N., Sakurai S., Asai A., Kirino T., and Hamada H. Over-expression of APAF-1 and caspase-9 augments radiation-induced apoptosis in U-373MG glioma cells. Int. J. Cancer 93 (2001) 252-261
127. Shinoura N., and Hamada H. Gene therapy using an adenovirus vector for apoptosis-related genes is a highly effective therapeutic modality for killing glioma cells. Curr. Gene Ther. 3 (2003) 147-153
128. Sinn P.L., Sauter S.L., and McCray Jr. P.B. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 12 (2005) 1089-1098
129. Spencer D.M., Wandless T.J., Schreiber S.L., and Crabtree G.R. Controlling signal transduction with synthetic ligands. Science 262 (1993) 1019-1024
130. Spyridonidis A., Schmitt-Graff A., Tomann T., Dwenger A., Follo M., Behringer D., and Finke J. Epithelial tissue chimerism after human hematopoietic cell transplantation is a real phenomenon. Am. J. Pathol. 164 (2004) 1147-1155
131. Stevens L.C. Studies on transplantable testicular teratomas of strain 129 mice. J. Natl. Cancer Inst. 20 (1958) 1257-1275
132. Strelchenko N., Verlinsky O., Kukharenko V., and Verlinsky Y. Morula-derived human embryonic stem cells. Reprod. Biomed. Online 9 (2004) 623-629
133. Strulovici Y., Leopold P.L., O'Connor T.P., Pergolizzi R.G., and Crystal R.G. Human embryonic stem cells and gene therapy. Mol. Ther. 15 (2007) 850-866
134. Tada M., Takahama Y., Abe K., Nakatsuji N., and Tada T. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr. Biol. 11 (2001) 1553-1558
135. Takahashi K., and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006) 663-676
136. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007) 861-872
137. Taylor H.S. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA 292 (2004) 81-85
138. Templeton N.S. Gene and Cell Therapy, Therapeutic Mechanisms and Strategies (2008), Taylor & Francis Group, New York, NY
139. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., and Jones J.M. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998) 1145-1147
140. Tiberghien P., Ferrand C., Lioure B., Milpied N., Angonin R., Deconinck E., Certoux J.M., Robinet E., Saas P., Petracca B., et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97 (2001) 63-72
141. Tolar J., and Neglia J.P. Transplacental and other routes of cancer transmission between individuals. J. Pediatr. Hematol. Oncol. 25 (2003) 430-434
142. Tran S.D., Pillemer S.R., Dutra A., Barrett A.J., Brownstein M.J., Key S., Pak E., Leakan R.A., Kingman A., Yamada K.M., et al. Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study. Lancet 361 (2003) 1084-1088
143. Traversari C., Marktel S., Magnani Z., Mangia P., Russo V., Ciceri F., Bonini C., and Bordignon C. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 109 (2007) 4708-4715
144. Unfer R.C., Hellrung D., and Link Jr. C.J. Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer Res. 63 (2003) 987-993
145. Vogel G. Cell biology. Ready or not? Human ES cells head toward the clinic. Science 308 (2005) 1534-1538
146. Weimann J.M., Charlton C.A., Brazelton T.R., Hackman R.C., and Blau H.M. Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brains. Proc. Natl. Acad. Sci. USA 100 (2003) 2088-2093
147. Wernig M., Meissner A., Foreman R., Brambrink T., Ku M., Hochedlinger K., Bernstein B.E., and Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448 (2007) 318-324
148. Wernig M., Meissner A., Cassady J.P., and Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2 (2008) 10-12
149. Wu X., and Burgess S.M. Integration target site selection for retroviruses and transposable elements. Cell. Mol. Life Sci. 61 (2004) 2588-2596
150. Wu A.M., and Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23 (2005) 1137-1146
151. Xie X., Zhao X., Liu Y., Zhang J., Matusik R.J., Slawin K.M., and Spencer D.M. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 61 (2001) 6795-6804
152. Yamanaka S. Pluripotency and nuclear programming. Philos. Trans. R Soc. Lond. B Biol. Sci. 363 (2008) 2079-2087
153. Yerushalmi N., Brinkmann U., Brinkmann E., Pai L., and Pastan I. Attenuating the growth of tumors by intratumoral administration of DNA encoding Pseudomonas exotoxin via cationic liposomes. Cancer Gene Ther. 7 (2000) 91-96
154. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007) 1917-1920
155. Zanzonico P., Koehne G., Gallardo H.F., Doubrovin M., Doubrovina E., Finn R., Blasberg R.G., Riviere I., O'Reilly R.J., Sadelain M., and Larson S.M. [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. Eur. J. Nucl. Med. Mol. Imaging 33 (2006) 988-997
156. Zhang X., Stojkovic P., Przyborski S., Cooke M., Armstrong L., Lako M., and Stojkovic M. Derivation of human embryonic stem cells from developing and arrested embryos. Stem Cells 24 (2006) 2669-2676